( tected in 11/52 treated patients. The ...)ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin,Conjugate Data Presented at American Diabetes Association Annual,Meeting,Health

tected in 11/52 treated patients. The drug was well-tolerated with no drug-related serious adverse events during the study.

In addition, the study titled "Safety and Pharmacodynamics of CJC-1134-PC, a Novel GLP-1 Receptor Agonist, in Patients with Type 2 Diabetes Mellitus: A Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Study", authored by Maggie Wang et al., was also featured as a poster session. This study evaluated the safety and efficacy of escalating single doses of CJC-1134-PC in 58 patients who had discontinued their oral antidiabetic agents for greater than or equal to 1 week and were randomized to either active drug or placebo in 6 escalating cohorts (PC-DAC(TM):Exendin-4 from 0.31mg to 5.0mg). Doses of greater than or equal to 1.25mg produced rapid and long-lasting reductions in mean daily glucose and fasting plasma glucose levels, persisting for at least 7 days after the single injection. In a separate cohort of 16 patients (12 active and 4 placebo) treated with either a single dose of 3mg PC-DAC(TM):Exendin-4 or placebo, a mean reduction in body weight of 2.5 kg (vs. 1.2 kg for placebo) was observed at the end of the 3-week in-clinic stay on a controlled diet. No significant safety or tolerability issues were reported at dose levels up to 3 mg.

Abstracts for the event can be found on the ADA's website at http://scientificsessions.diabetes.org

About PC-DAC(TM):Exendin-4

Exendin-4, like Glucagon-like peptide-1 (GLP-1) is an insulinotropic peptide and an agonist for the GLP-1 receptor. Exendin-4 decreases glucagon and increases insulin secretion in a glucose-dependent manner. Exendin-4 may stimulate beta-cell proliferation, restore beta-cell sensitivity to glucose, delay gastric emptying, and increase peripheral sensitivity to glucose. The clinical util
'"/>

Page: 1 2 3
Related medicine technology :

1. News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics
2. Gemin X Biotechnologies Announces Publication in Blood of Positive Preclinical Data of Lead Compound in Mantle Cell Lymphoma
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine